Evogene Ltd. (TLV:EVGN)
Israel · Delayed Price · Currency is ILS · Price in ILA 143.60
-11.90 (-7.65%)
Aug 3, 2026, 5:24 PM IDT
Evogene Market Cap
Evogene has a market cap or net worth of 15.12 million as of August 3, 2026. Its market cap has decreased by -57.73% in one year.
Market Cap
15.12M
Enterprise Value
13.58M
Revenue
5.82M
Ranking
n/a
PE Ratio
n/a
Stock Price
143.60
ChartMarket Cap Chart
Since October 15, 2007, Evogene's market cap has decreased from 113.15M to 15.12M, a decrease of -86.64%. That is a compound annual growth rate of -10.15%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 3, 2026 | 15.12M | -42.30% |
| Dec 31, 2025 | 26.20M | -44.67% |
| Dec 31, 2024 | 47.35M | -68.75% |
| Dec 31, 2023 | 151.55M | 64.52% |
| Dec 29, 2022 | 92.12M | -58.37% |
| Dec 30, 2021 | 221.26M | -59.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Geffen Residence & Renewal | 322.94M |
| Bonus BioGroup | 309.56M |
| Matricelf | 72.59M |
| BioLineRx | 41.94M |
| Clal Biotechnology Industries | 40.47M |
| BioLight Life Sciences | 31.56M |
| Can-Fite BioPharma | 22.11M |
| XTL Biopharmaceuticals | 19.66M |